BioSpace News Archive

AAC Holdings, Inc. (NYSE: AAC) has announced the hiring of Stephen Ebbett as its Chief Digital & Marketing Officer, reporting to Chairman & Chief Executive Officer, Michael Cartwright.

AMDT Holdings, Inc. (AMDT) is pleased to announce FDA clearance for their patented SixFix deformity analysis and correction software and instrumentation.

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking action to help people in Mississippi, Alabama and Louisiana affected by Tropical Storm Gordon.

SERAXIS Inc. today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes.

Both TCRs discovered by Novel “T-Rx™" Discovery Platform

AbbVie, a research-based global biopharmaceutical company, today announced its annual call for the public to vote for students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system, as part of its 2018 Thriving Student Scholarship.

According to a recent article in the International Journal of Spine Surgery, advanced decompression innovator Carevature’s Dreal™ device yields significantly better results in incidental dural tears, with 87% improvement compared to high-speed drills and Kerrison Rongeurs (0.4% vs. 2.91%; p<0.01); and 80% improvement compared to ultrasonic bone cutters (0.4% vs. 1.95%; p<0.01).

Waters Corporation (NYSE:WAT) Chris O’Connell, Chairman and Chief Executive Officer, will speak to the investment community at the Morgan Stanley 16th Annual Global Healthcare Conference to be held at the Grand Hyatt New York, Wednesday, September 12, at 9:55 AM Eastern Time.

New analysis from the American Academy of Actuaries, “Travel Insurance: An Actuarial Perspective,” draws on actuarial expertise to provide a clear explanation of what coverage travel insurance may or may not provide, how travel insurance differs from other types of insurance, and the public policy considerations involved in regulating this unique line of insurance.

Advicenne announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ADV7103.